+

WO1988003953A1 - Bioadhesifs - Google Patents

Bioadhesifs Download PDF

Info

Publication number
WO1988003953A1
WO1988003953A1 PCT/US1987/003048 US8703048W WO8803953A1 WO 1988003953 A1 WO1988003953 A1 WO 1988003953A1 US 8703048 W US8703048 W US 8703048W WO 8803953 A1 WO8803953 A1 WO 8803953A1
Authority
WO
WIPO (PCT)
Prior art keywords
pro
lys
thr tyr
cca
tat
Prior art date
Application number
PCT/US1987/003048
Other languages
English (en)
Inventor
Kathy J. Maugh
David M. Anderson
Robert Strausberg
Susan L. Strausberg
Russ Mccandliss
Tena Wei
David Filpula
Original Assignee
Genex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genex Corporation filed Critical Genex Corporation
Priority to JP88501325A priority Critical patent/JPH02501706A/ja
Publication of WO1988003953A1 publication Critical patent/WO1988003953A1/fr
Priority to DK414688A priority patent/DK414688D0/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • This invention relates to the production of bio- adhesives that can be employed to bond substances for use in wet environments.
  • the bioadhesives of the invention are employed as marine adhesives, biomedical adhesives or dental adhesives.
  • the invention further relates to the microbial production of bioadhesive presursor proteins that can be converted to bioadhesives by chemical or enzymatic treatment.
  • the properties of adhesives generally must be tailored to meet the requirements of the particular environnents in which they are to be used. Ideally, an adhesive should be cured and it should maintain both its adhesivity and cohesivity under the conditions of use. Curing is the altering of the physical properties of an adhesive by chemical or enzymatic means. In the case of the bioadhesives produces by the procesures described herein, curing is likely to be due to the cross-linking of adjacent uncured adhesive molecules by catalytic and/or chemical agents. Curing may also involve adhesive cross-linking with the substrate. Many adhesives that exhibit excellent adhesive properties under dry conditions suffer a substantial or total loss of those properties in wet environments. Furthermore, adhesives of the prior art cannot be cured in vet environments. Consequently, it has been particularly difficult to develop adhesives for use in wet environments, such as marine adhesives or adhesives for use in medical and dental applications.
  • Marine mussels and other sessile invertebrates have the ability to secrete adhesive substances by which they affix themselves to underwater objects.
  • mussels of the genus Mytilus e.g., the species Mytilus edulis and Mytilus californianus
  • deposit an adhesive substance from the mussel foot that becomes cured, forming a permanent attachment to the substrate.
  • a major component of the adhesive plaque deposited by M. edulis has been identified as a hydroxylated protein of about 130,000 daltons (Waite, J. H., J. Biol. Chem., 258: 2911-2915 (1983)).
  • U.S. Patent No. 4,585,585 describes a procedure for preparing a bioadhesive polymer by chemically linking decapeptide units produced by the enzymatic digestion of isolated mussel adhesive protein.
  • a bioadhesive protein is first isolated from phenol glands of mussels of the genus Mytilus using the protein purification procedures described by Waite and Tanzer in Science, 212:1038 (1981).
  • the isolated bioadhesive having a molecular weight of 120,000 to 140,000 daltons, is first treated with collagenase, which reduces its molecular weight by about 10,000 daltons.
  • the treated protein is then digested with trypsin, and the digested protein subjected to gel filtration dialysis to isolate decapeptides of the general formula
  • decapeptides produced in this manner are then polymerized by the use of chemical linking groups such as glutaraldehyde,. oligopeptides, amino acids or other, bifunctional linking groups to produce bioadhesives containing up to about 1,000 such decapeptide units.
  • chemical linking groups such as glutaraldehyde,. oligopeptides, amino acids or other, bifunctional linking groups to produce bioadhesives containing up to about 1,000 such decapeptide units.
  • This invention involves application of the techniques of recombinant DNA technology to the production of bioadhesives of the type produced by marine animals such as mussels, barnacles and oysters.
  • bioadhesives of the type produced by marine animals such as mussels, barnacles and oysters.
  • native bioadhesive precursor proteins also termed polyphenolic proteins
  • the bioadhesive precursor proteins are chemically or enzymatically hydroxylated, mimicking a process which occurs in vivo in the mussel, to produce a bioadhesive protein which cures to produce an adhesive having excellent properties in wet environments.
  • Another encoded protein, from cDNA isolate 55, has homology with 53 and 110 amino acids in the proteins encoded by cDNAs 14-1 and 52, as well as homology in a different region with 34 and 57 amino acids of the proteins encoded by cDNA isolates 56 and 52.
  • the coding homologies are conserved at the DNA level.
  • M. edulis polyphenolic protein gene consists of several exons that can be spliced together in different combinations at the mRNA level. Alternatively, there could be several closely related. genes.
  • a further encoded protein from cDNA isolate Nl, a 2.1 kb clone, contains 76 continuous tandem repeats of decapeptides and hexapeptides.
  • 32 display non-homology with the decapeptide described in U.S. Patent 4,585,585.
  • a DNA segment comprising codons for the native amino acid sequence of a bioadhesive precursor protein of a marine animal, e.g., of a mussel of the genus Mytilus, e.g., M. edulis.
  • vectors are provided for expression of bioadhesive precursor protein comprising:
  • a promoter and transcription initiation signal operably linked to said DNA segment, which are capable of effecting microbial expression of the bioadhesive precursor protein.
  • transformant microorganisms capable of expressing bioadhesive precursor proteins that can be chemically or enzymatically converted to a bioadhesive.
  • the transformants are produced by transforming a host microorganism such as an E. coli or Saccharomyces cerevisiae with the aforementioned expression vector.
  • a method of producing a bioadhesive protein A transformant microorganism containing the expression vector for the bioadhesive precursor protein is cultured and subjected to conditions under which the precursor protein is expressed and the precursor protein is recovered.
  • the precursor protein contains amino acid sequence subunits which possess tyrosine and proline residues.
  • the precursor protein is converted into a bioadhesive protein by chemical or enzymatic hydroxylation, which converts at least a portion of the tyrosine residues to 3,4-dihydroxyphenylalanine (DOPA) residues and, optionally, at least a portion of the proline residues to hydroxyproline residues.
  • DOPA 3,4-dihydroxyphenylalanine
  • the bioadhesive precursor protein is hydroxylated by enzymatic treatment, for example, with mushroom tyrosinase.
  • FIG. 1 presents the DNA sequence and translated amino acid sequence of a gene identified as cDNA clone
  • FIG. 2 presents the DNA sequence and translated amino acid sequence of a gene identified as cDNA clone
  • FIG. 3 presents the DNA sequence and translated amino acid sequence of a gene identified as cDNA clone
  • FIG. 4 presents the DNA sequence and translated amino acid sequence of a gene identified as cDNA clone
  • FIG. 5(a) presents the sequence of a portion of a multi-restriction site region of plasmid pGX2627.
  • Fig. 5(b) presents a DNA sequence and translated amino acid sequence of portions of a synthetic DNA segment employed in the construction of plasmid pGX2346 from plasmid pGX2287.
  • FIG. 6 is a schematic representation of the construction of plasmids pGX2346, pGX2368, pGX2377, pGX2380, pGX2381 and pGX2383.
  • Plasmid pGX2383 is an expression vector for a bioadhesive precursor protein.
  • FIG. 7 is the DNA sequence of plasmid pGX2627.
  • FIG. 8 is a restriction map of the YpGX265GAL4 shuttle vector showing the position and orientation of the major functional elements, including the GAL4 binding site, the MF-alpha 1 transcription initiation site, the PHO5 signal encoding sequence, the GAPDH terminator sequence, the E. coli ampicillin-resistance marker and the LEU2 marker for plasmid selection in S. cerevisiae.
  • Figure 9 presents the DNA sequence and translated amino acid sequence of a gene identified as cDNA clone Nl, which codes for a bioadhesive precursor protein of M. edulis.
  • Figure 10 presents the amino acid variations in decapeptides of clone Nl. The variations in each position are shown, with the subscripts indicating the number of decapeptides in clone Nl in which the particular amino acid occurs at the position cited.
  • Figure 11 is a restriction map of YpGX283, showing the position and orientation of the major functional elements.
  • Figure 12 is a restriction map of plasmid YpGX405 yeast E. coli shuttle vector, showing the position and orientation of major functional elements.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The preparation of an expression vector of the invention generally involved the following series of steps:
  • the mRNA can be isolated from M. edulis by isolating the foot organ containing the phenol gland from live mussels; homogenizing the tissue in liquid nitrogen; dissolving the frozen tissue in guanidine thio- cyanate as described by McCandliss, R. et al., Methods Enzymol., 79:51-57 (1981), or lysing the frozen tissue in the presence of ribonucleoside-vanadyl complexes and extracting the lysed tissue with phenol as described by Berger, S. et al. , J. Biol.
  • mRNA extracted i.e., from the phenol glands
  • mRNA extracted is then employed as a template to produce cDNA in the presence of reverse transcriptase, dATP, dCTP, dGTP and dTTP, according to well-known procedures.
  • a radioactive marker such as
  • [alpha- 32 P]dCTP is used to monitor the synthesis.
  • the mRNA moiety is then removed using known procedures and a second strand of cDNA is synthesized, using thefirst strand as a template, in the presence of E. coli DNA polymerase I (Klenow fragment), dATP, dCTP, dGTP and dTTP.
  • E. coli DNA polymerase I Klenow fragment
  • dATP dCTP
  • dGTP dGTP
  • dTTP double-stranded
  • the ds-cDNA produced in the manner described is then inserted into a cloning vector in order to produce a library of clones to screen for the presence of the bioadhesive precursor protein gene.
  • a cloning vector was employed as a cloning vector; however, those skilled in the art will be aware that any of numerous other vectors could conveniently be employed to the same end.
  • the cloning vector containing the cDNA is propagated in a suitable host.
  • a suitable host In the case of the recombinant lambda gt10, we packaged the recombinant phage DNA into bacteriophage lambda heads for introduction into E. coli strain BNN102 (Huynh, T.V. et al., Constructing and screening cDNA libraries in lambda gtlO and lambda gt11, In:D.M. Glover (ed.) DNA cloning. Vol. I, IRL Press, Oxford (1985), pp. 49-78) by procedures described by Enquist and Sternberg, Methods Enzymol., 68:281-298 (1979).
  • E. coli strain BNN102 Huynh, T.V. et al., Constructing and screening cDNA libraries in lambda gtlO and lambda gt11, In:D.M. Glover (ed.) DNA
  • the ds-cDNA library produced in the above manner is screened for the presence of the bioadhesive precursor protein gene by hybridization with a radio- labeled synthetic oligonucleotide probe.
  • One predominant decapeptide in the bioadhesive precursor protein is known to be ala-lys-pro-ser-tyr-pro-pro- thr-tyr-lys.
  • To screen the recombinant phage library for the precursor protein gene we constructed and radiolabeled two 30-base synthetic oligonucleotide probes coding for the decapeptide, these two selected randomly from the 98,304 possible coding combinations. The two sequences selected were GCG AAA CCA AGT TAC CCA CCG ACC TAC AAA and GCG AAA CCT TCT TAT CCG CCT ACC TAT AAG.
  • the radiolabeled probes were used to screen plaques which had been fixed on duplicate nitrocellulose filter replicates.
  • the 30-base probes are the shortest synthetic probes that have been used successfully in this type of screening. Plaques that gave positive signals by autoradiography of duplicate filters were purified, screened again and grown as plate lysates for DNA preparation as described in Maniatis, T. et al., "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Laboratory, pp. 371-372 (1982).
  • the DNA sequence of the isolated clones can be determined by well-known methods.
  • clones 14-1, 52, 55, 56, and Nl which contained DNA sequences coding for bioadhesive precursor proteins.
  • Fig. 1 presents the DNA sequence and the translated amino acid sequence of the insert in clone 14-1.
  • the DNA segment comprising the insert in clone 14-1 contains codons for a 203-amino acid sequence.
  • the sequence has been divided to show 20 subunits, including 19 decapeptides and 1 hexapeptide (subunit no. 8).
  • Fig. 2 presents the DNA sequence and the translated amino acid sequence from the insert in cDNA clone 52.
  • This DNA segment in the insert in cDNA clone 52 contains codons for a 334-amino acid sequence.
  • the sequence has been divided to show 26 subunits which include 23 decapeptides and 3 hexapeptides, and an amino-terminal proline-rich segment.
  • This cDNA clone and two of the other analyzed clones contain some noncoding DNA sequence (not shown) which we believe is derived from intron sequences. This suggests that some of the clones were derived from incompletely processed nuclear RNA.
  • the DNA sequences of the cDNA clones 14-1 and 52 display extensive homology at their 3'-ends.
  • the last 138 codons of the translated regions are identical and include codons for a hexapeptide followed by 12 decapeptides (beginning at codon 75 of clone 14-1 in Figure 1 and codon 205 of clone 52 in Figure 2).
  • Clone 52 contains a segment at the 5'-end that codes for a proline-rich segment of 82 amino acids.
  • Codons 19-129 of cDNA clone 55 match the codons 148-259 of cDNA clone 52 with one exception.
  • Codon 65 of clone 55 is an alanine while the clone 52 corresponding codon 195 is isoleucine.
  • Clone Nl does not have a perfect overlap with any of clones 14-1, 52, 55 or 56. Clone Nl also does not have a characteristic 5'-end sequence and therefore does not, in all likelihood, include the N-terminus of the natural gene. It does, however, code for a polypeptide with a molecular weight of about 80,000, a substantial portion of the natural polypeptide (molecule weight of 110,000-130,000).
  • cDNA clones are related in a complex way. Although there are areas in common, there is also generally divergence, suggesting either the existence of multiple genes or varied patterns of mRNA splicing for one gene or both.
  • this invention provides expression vectors for microbial expression of bioadhesive precursor proteins.
  • the expression vectors contain a DNA segment coding for a bioadhesive precursor protein such as that of a mussel of the genus Mytilus or a fragment thereof, the DNA segment being operably linked to a promoter and transcription initiation signals that are capable of effecting microbial expression.
  • the DNA segment contains codons for at least the portion of the amino acid sequence comprising subunits 8-20 of clone 14-1 and subunits 14-21 of clone 52; that is, amino acids 72-197 of clone 14-1 and amino acids 201-326 of clone 52.
  • FIGS 6 and 7 outline one procedure that is employed to produce expression vectors of the invention.
  • These expression vectors are capable of effecting expression of a bioadhesive precursor protein as a hybrid fusion protein which, in some cases, contains a methionine residue just upstream of the protein of interest. Since the bioadhesive precursor proteins encoded by all of the clones described above except clone Nl contain no methionine residues, they can be conveniently separated from the fused sequences by treatment with cyanogen bromide, which cleaves the fusion protein at methionine residues.
  • cyanogen bromide treatment may cleave at the methionine residue found in the second decapeptide, still leaving essentially the entire polypeptide intact.
  • the amino-terminal non-bioadhesive precursor protein amino acids will comprise at most roughly 15%, and in many cases much less, of the total adhesive protein precursor, removal of those amino acids by cyanogen bromide cleavage will not be necessary for all applications.
  • the DNA segment containing the coding region for the bioadhesive precursor protein of clones 14-1 and 52 was obtained from the lambda gt10 cloning vectors by EcoRI digestion and. subcloned into the EcoRI site of plasmid pGX2627.
  • the resultant plasmids were designated pGX2368 and PGX2377.
  • Plasmids pGX2368 and pGX2377 were subjected to oligonucleotide-directed mutagenesis (Zoller, M.J. et al., Methods Enzymol., Vol 100B, R. Woo, L. Grassa, and K. Moldave (eds.), Academic Press, New York, pp. 468-500 (1983)) to create Bell sites located at the translation terminators of each gene (see Figs. 1 and 2). Since pGX2627 is a derivative of pGXl066 (ATCC No.
  • the pGX2368 and pGX2377 derivatives of pGX2627 were isolated in a single-stranded form for the oligonucleotide-directed mutagenesis experiments by infection of cultures with IRl or M13 bacteriophage.
  • the new plasmids containing Bell sites were designated pGX2380 and pGX2381.
  • E. coli and yeast expression vectors were then inserted into E. coli and yeast expression vectors in the proper reading frame.
  • E. coli E. coli example presented below, the cDNA from phage 14-1 located in pGX2380 was cloned as a trpB gene fusion starting with an expression vector identified as pGX2287 that was designed for bovine chymosin production. Construction of this vector is described in detail in copending, commonly assigned U.S. Application Serial No. 671,976. Plasmid pGX2287 has been deposited with the USDA Northern Regional Research Laboratory, Peoria, Illinois, with accession No. NRRL-B15788.
  • trpB bovine chymosin gene under the control of the leftward operator and rightward promoter regions of phage lambda (see copending, commonly assigned U.S. application Serial No. 534,982) and an appropriately positioned transcription initiation signal. It also contains an ampicillin-resistance gene.
  • Plasmid pGX2287 was cut with Clal, which cleaved the plasmid in trpB 24-base pairs upstream from the 5'-end of the chymosin coding sequence.
  • a 116-base pair Clal-Sphl synthetic DNA was then ligated with linearized plasmid.
  • the sequence of the synthetic DNA fragment which was ligated to the linearized plasmid is given in Fig. 5(b).
  • the ligated DNA was then digested with SphI and the large fragment was isolated, resulting in the removal of a substantial portion of the chymosin coding region.
  • the plasmid was then recircularized with T4 ligase.
  • the resultant plasmid, identified pGX2346 contained the synthetic DNA fragment in place of the central portion of the chymosin gene.
  • the vector by inserting the bioadhesive precursor coding region as an in-frame fusion with another gene that is under the control of an efficient promoter.
  • the fusion is constructed such that the encoded fusion protein contains a methionine residue just upstream, e.g., within about 10 residues, from the bioadhesive precursor protein segment.
  • pGX2383 there is a methionine residue 7 amino acids upstream from the bioadhesive precursor sequence.
  • the recovered bioadhesive precursor protein can be treated with cyanogen bromide, using conditions well-known in the art, to remove extraneous amino acid sequences.
  • cyanogen bromide cleaves proteins at methionine residues. Since there are no internal methionine residues within the bioadhesive precursor protein itself, the protein remains intact.
  • the expression vector can carry the entire coding region for the bioadhesive precursor protein or a coding region for a fragment thereof.
  • the fragment contains at least about 5-20% of the coding sequence of a native bioadhesive precursor protein of a marine animal, e.g., of a mussel, e.g., of a mussel of the genus Mytilus.
  • Encoded amino acids fused to the N-terminal or C-terminal ends of the encoded bioadhesive precursor which cannot be removed by cyanogen bromide cleavage, are not believed to interfere with the functioning of the bioadhesive protein.
  • the expression vector provided by the invention is used to transform any suitable host microorganism, using known means, to produce a transformant.
  • Suitable host organisms include, for example, E. coli or other related gram-negative organisms such as Salmo nella, Klebsiella, Erwinia, etc.
  • the host preferably contains the lambda cI857 gene coding for temperature-sensitive lambda represser.
  • E. coli strain GX3015 as the host. This was because pGX2383 contains the trpED portion deleted in the trpED102 chromosomal deletion in GX3015. The plasmid is therefore stabilized by growing the transformant in a tryptophan-deficient medium.
  • an expression vector may be used to transform yeast, e.g., Saccharomyces cerevisiae.
  • yeast e.g., Saccharomyces cerevisiae.
  • Typical vectors of this type are disclosed in U.S. application Serial No. 918,147, filed on October 14, 1986, and having the title "Composite Yeast Vectors," incorporated by reference herein.
  • One preferred vector for expression of bioadhesive precursor protein in yeast comprises the yeast shuttle vector YpGX265GAL4 (ATCC #67233). This vector is characterized by a promoter that is a hybrid-derived from the S. cerevisiae GAL1 and MF-alpha 1(alpha-factor) promoters. This promoter system permits galactose-regulated expression.
  • the regulatory gene comprises the GAL4 gene which encodes GAL4 protein, a positive regulator of the GALl-MF-alpha 1 hybrid promoter derived from S. cerevisiae.
  • the terminator in the YpGX265GAL4 vector system is derived from synthetic DNA and is based on S. cerevisiae GAPDH transcription terminator.
  • the signal encoding sequence, also derived from synthetic DNA, is based on the S. cerevisiae PH05 signal. Codons are designed substantially for usage preference in S. cerevisiae.
  • the YpGX265GAL4 vector contains the LEU2 gene, a marker for plasmid selection in S. cerevisiae. It also contains DNA derived from S. cerevisiae 2-micron plasmid which provides a plasmid replication origin for S. cerevisiae.
  • the vector is further characterized by the E. coli replication origin derived from pAT153, and an E. coli selectable marker which is ampicillin resistance, also derived from pAT153.
  • the heterologous gene (the gene coding for bioadhesive precursor protein) is inserted between the PH05 signal-encoding sequence and the GAPDH terminator.
  • a typical shuttle vector preparation is as follows.
  • YpGX265GAL4 is digested with restriction endonuclease Hindlll and large and small DNA fragments are gel-purified.
  • the larger fragment is digested with restriction endonuclease Smal, generating two DNA fragments.
  • M13mp9 (commercially available) is digested with Smal and Hindlll and treated with calf alkaline phosphatase.
  • the DNA fragments created by the Smal digestion of the larger Hindlll fragment of YpGX265GAL4 and from digestion of the M13mp9 are ligated and used for transformation of E. coli.
  • the transformants containing phage double-stranded DNA with the yeast promoter-terminator cassette are identified, digested with restriction endonucleases (EcoRV and BamHI) and the large fragment (approximately 8 kilobase) is gel-purified.
  • a plasmid containing bioadhesive precursor protein cDNA i.e., pGX2380
  • pGX2380 is digested with restriction endonuclease Xbal
  • the single-stranded overhang is filled with the Klenow fragment of DNA polymerase.
  • the DNA molecule resulting from the Xbal and DNA polymerase treatment of pGX2380 is digested with Bcll.
  • the resulting approximately 625-bp DNA fragment is gel-purified.
  • Oligonucleotide linker sequences are annealed and used in a three-way ligation with the DNA fragments created by restriction of the phage double-stranded DNA and the cDNA-derived DNA molecule with the modified Xbal and Bell end.
  • E. coli transformants containing the desired phage DNA molecules are identified by restriction endonuclease digestion.
  • This phage DNA may be digested with restriction endonucleases (Smal and Hindlll), with the small (approximately 1,300 base pair) fragment gel-purified.
  • YpGX265GAL4 is digested with Smal and Hindlll and the large fragment is gel-purified.
  • the DNA molecules created by the Smal-HindiII digestions are ligated and used to transform E. coli.
  • the desired plasmid may be linearized with restriction endonuclease (Hindlll) and treated with calf alkaline phosphatase.
  • the 3.65-kb GAL4-containing fragment obtained from the original restriction digestion may by ligated with the linearized DNA and used to transform E. coli.
  • Saccharomyces strains carrying mutations in the LEU2 structural gene may be transformed with this plasmid, utilizing standard methods.
  • the yeast strain may be grown in an appropriate medium (YNBD, containing 0.7% yeast nitrogen base, 2% glucose, 20 mg/liter L-histidine) to maintain the plasmid.
  • the expression vector may comprise the entire coding region for the bioadhesive precursor protein or coding regions for fragments thereof.
  • the transformed yeast strain may be grown in an appropriate medium.
  • One suitable medium contains 1% yeast extract, 2% peptone, 1% glucose, and 1% galactose.
  • the transformant microorganism is cultured under conditions suitable for growth and expression of the bioadhesive precursor protein gene. After the protein has been expressed, it is recovered from the transformant by known methods such as by mechanical or chemical lysis of the cells.
  • the protein can be purified using procedures known in the art, including well-known chromatographic procedures.
  • the bioadhesive precursor protein is preferably purified to homogeneity or near homogeneity. In the case of a fusion protein such as that expressed by pGX2383, the recovered protein can be subjected to cyanogen bromide cleavage to remove extraneous peptide sequences.
  • the recovered bioadhesive precursor protein is converted to a bioadhesive by hydroxylation.
  • hydroxylation converts tyrosine residues to DOPA residues and, optionally, proline residues to hydroxy proline residues.
  • DOPA hydroxyl groups are believed to displace water at the bond surfaces, thus contributing to the excellent wet strength of the adhesive, and DOPA residues oxidized to quinones participate in intermolecular cross-linking which cures the adhesive and imparts cohesivity.
  • Any suitable chemical or enzymatic means for effecting hydroxylation can be employed. It is preferred, however, to effect hydroxylation enzymatically using an enzyme such as mushroom tyrosinase or Streptomyces antibioticus tyrosinase. Enzymatic hydroxyla tion procedures using these enzymes are carried out as generally described by Ito et al., Biochem. J. 222: 407-411 (1984) and Marumo and Waite, Biochem. Biophys. Acta 872:98-103 (1986). Preferably, at least about 10% of the tyrosine residues are hydroxylated.
  • the mushroom tyrosinase is removed from the protein using known procedures such as binding to a LH-Sephadex 60 column followed by elution with 0.2 M acetic acid or by membrane filtration.
  • the bioadhesive protein can be lyophilized for reconstitution as an adhesive formulation at a later date.
  • the bioadhesive protein can be employed in the form of a solution in a suitable solvent with or without other adhesive substances.
  • suitable solvents for the bioadhesive include water or aqueous solutions of alcohols such as methanol, ethanol, propanol, and the like, acetone, DMSO, dimethyl formamide, and the like.
  • the concentration of bioadhesive protein in the solution can range from very low to very high, depending upon the intended application.
  • the bioadhesive protein or a solution or formulation containing the bioadhesive protein can be employed as a primer, i.e., a preadhesive film or coating to improve the total adhesive bond to a surface. It may also be employed as a component in an adhesive system to impart or improve water-resistant adhesivity.
  • a primer i.e., a preadhesive film or coating to improve the total adhesive bond to a surface. It may also be employed as a component in an adhesive system to impart or improve water-resistant adhesivity.
  • Another use within the scope of the invention includes use as a thin film membrane, or as a component in a thin film or membrane, particularly to impart desirable permeability characteristics and/or moisture resistance to such film or membrane. Yet another use is as a sealant or component of a sealant to prevent moisture penetration.
  • a solution of the bioadhesive protein can be uniformly coated on a surface as a primer.
  • Curing of the primer coating occurs in a normal air environment by cross-linking, which may be indicated by the development of a brown or tan color when used in high concentration.
  • a conventional adhesive such as an epoxy adhesive is then applied over the primer coat and the surfaces to be bonded are brought together.
  • an adhesive composition that contains the hydroxylated bioadhesive protein in solution with another adhesive substance.
  • Typical of the adhesives that may be employed in conjunction with the bioadhesive protein of the invention are the carbohydrate adhesives and the synthetic resin adhesives such as the polyacrylates, polyepoxides, resols, etc.
  • the known carbohydrate adhesives that can be employed include chitosan, starch, pectin, glucan, dextran, etc.
  • a preferred carbohydrate adhesive is chitosan purified from crab or shrimp shell chitin by the procedure of Skujins, J. J. et al., Arch. Biochem. Biophys., 111:359 (1965).
  • the free amino groups of chitosan are reactive with the DOPA-derived quinones of oxidized bioadhesive protein, providing covalent cross-links between the two polymers.
  • whitosan at appropriate concentrations provides bioadhesive protein mixtures with a high viscosity and excellent adhesive strength.
  • the high viscosity is a particularly useful property in underwater applications where diffusion can cause a loss of material before the adhesive has an opportunity to cure.
  • a preferred adhesive mixture comprises from 0.1% to 30% of the hyroxylated bioadhesive polymer and from 1% to 7% chitosan, the balance being solvent.
  • the pH of the composition is from about 5.5 to 7.0.
  • the composition can be cured at pH 6.0 by the addition of catechol oxidase or tyrosinase which catalyzes the formation of DOPA-derived quinones and cross-linking.
  • an adhesive composition in which the bioadhesive protein is admixed with other proteins that improve its physical properties such as cohesivity.
  • a preferred protein for this protein is collagen.
  • a preferred composition comprises a solution having 0.1% to 70% solids, the solids in the solution comprising from 1% to 50% bioadhesive protein and from 50% to 99% collagen.
  • the bioadhesive protein of the invention is particularly useful as a biomedical adhesive or sealant in a variety of medical applications, for example, in wound healing. Being a biological material, the bioadhesive protein presents a greatly reduced risk of toxic degradation products as compared with a synthetic adhesive.
  • the bioadhesive protein can be applied as a biomedical sealant in much the same manner as fibrin (see e.g., Redl, A. and Schlag, C., Facial Plastic Surgery, 24:315-321 (1985)).
  • Synthetic decapeptide (1.5 mg) with the predominant sequence of M. edulis bioadhesive precursor protein (ala-lys-pro-ser-tyr-pro-pro-thr-tyr-lys) prepared by the Merrifield solid state method was combined with 2.0 mg of bovine serum albumin (BSA) in 1.8 ml phosphate-buffered saline. One percent glutaraldehyde (0.2 ml) was added and the solution was incubated 30 minutes at 22°C. Sodium borohydride was added to a final concentration of 0.5 mg/ml and incubation was continued at 22°C for one hour. The solution was then dialyzed against phosphate-buffered saline. Amino acid analysis of the resulting protein indicated 35 moles of peptide were coupled per mole of BSA.
  • BSA bovine serum albumin
  • the adductor muscles of live blue mussels (Mytilus edulis) were cut and the foot organ containing the phenol gland was amputated, quickly cut in small pieces and frozen in liquid nitrogen.
  • the frozen tissue was shattered into small pieces by mixing in liquid nitrogen at top speed in a commercial Waring blender with a metal container.
  • the pulverized tissue was stored at -80°C until use.
  • RNA isolation procedure McCandliss, R. et al., Methods Enzy mol, 79:51-59 (1981)). From 22.1 g wet weight of tissue, 28.3 mg of total RNA was obtained. Poly A-containing RNA was purified by selecting the RNA that would bind to oligo-dT cellulose (Aviv, H. and P. Leder, Proe. Natl. Acad. Sci. USA 69:1408-1412 (1972)). Two oligo-dT cellulose selections yielded 0.6% of the total RNA (approximately 170 ug) that included polyadenylated mRNA.
  • RNA (with some genomic DNA) was precipitated with ethanol.
  • Poly A-containing RNA was purified as above. From 5 g of tissue, approximately 150 ug of poly A RNA were isolated.
  • Oligo (dT) 12-10 1,000 ug/ml (Collaborative Research, Waltham, Mass.)
  • RNasin ribonuclease inhibitor 30 units/ul, (Promega Biotec)
  • AMV Avian myeloblastosis virus reverse transcriptase
  • mRNA prepared by the guanidine method described in Example 2 was employed as a template for cDNA synthesis.
  • a radio- active marker [alpha- 32 P]dCTP) was used. This allows monitoring of all steps by counting Cerenkov radiation, which does not result in any loss of sample.
  • 2 uCi of [alpha- 32 P]dCTP at a specific activity of 400 Ci/mmol were used.
  • the radioactive material was added to a 2X reaction mixture consisting of 0.
  • This solution was kept on ice.
  • To this solution was added mRNA (50 ug/ml, final concentration), oligo (dT) 12 -18 (100 ug/ml), RNasin (600 units/ml), AMV reverse transcriptase (800 units/ml), and enough water to dilute the 2X mix to IX. After 5 minutes on ice, the reaction mixture was incubated at 46°C for 10 minutes.
  • EDTA was added to a final concentration of 25 mM.
  • the solution was extracted one time with an equal volume of phenol:chloroform (1/1; v/v) and the aqueous phase was chromatographed on a column of Sephadex G-100 (0.7 x 20cm) equilibrated with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl.
  • the mRNA:cDNA hybrid in the excluded volume was precipitated by addition of 0.1 volume of 3 M sodium acetate and 2 volumes of 95% ethanol (-20°C to -80°C).
  • the pelleted hybrid was dissolved in 300 ul 0.1 M NaOH and incubated at 70°C for 20 minutes. The solution was cooled on ice and neutralized with 30 ul of IN BC1. The cDNA was precipitated as described above. Stock Solutions and Materials for Second Strand cDNA Synthesis
  • E. coli DNA polymerase I (Klenow fragment), approximately 5,000 units/ml (Boehringer- Mannheim)
  • 10X SI nuclease buffer 0.5 M sodium acetate, pH 4.5; 10mM ZnSO 4 , 2 M NaCl, 5% glycerol.
  • a 2X reaction mixture consisting of 0.2 M potassium phosphate, pH 7.4, 20 mM MgCl 2 , 2 mM DTT, 0.4 mM each of dATP, dGTP, dCTP, and dTTP was prepared and kept on ice. To this mixture was added an aqueous solution of cDNA containing the Klenow fragment of E. coli DNA polymerase I (100 units/ml, final concentration), and water was added to dilute the reaction mixture to 1X. The solution was incubated overnight at 15oC.
  • EDTA was added to 25 mM, the solution was extracted once with an equal volume of phenol: chloroform (1/1; v/v), and the aqueous phase was chromatographed on a 0.7 x 20 cm column of Sephadex G-100 equilibrated with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 0.1 M NaCl. The DNA in the excluded fractions was precipitated with ethanol as described above.
  • the ds-cDNA was in the form of a hairpin.
  • the single-stranded loop was removed by digestion with SI nuclease .
  • the ds-cDNA was dissolved in water and 0.1 volume of 10X SI buffer was added.
  • An appropriate amount of SI nuclease was added and the solution was incubated 20 minutes at 37°C.
  • the amount of enzyme added was determined empirically for each enzyme preparation, since the activity varied from one preparation to another. This was done by measuring the decrease in TCA-precipitable counts from the ds- cDNA. Generally, a decrease of 20-40% was observed.
  • the Sl-digested cDNA was extracted once with phenol: chloroform and the cDNA in the aqueous phase was precipitated with ethanol as described above.
  • SAM S-adenosyl methionine
  • bovine serum albumin (BSA) -- solution in water, sterile filtered.
  • 10 x T4 polynucleotide kinase buffer 0.7 M Tris-HCl, pH 7.6, 0.1 M MgCl 2 , 50 mM dithiothreitol.
  • gamma[ 32 P]-ATP 10 mCi/ml, 2,000 Ci/mmol, stabilized aqueous solution.
  • 10 x T4 ligase buffer 0.5 M Tris-HCl, pH 7.8, 0.1 M MgCl 2 , 0.2 M dithiothreitol.
  • the cDNA fragment produced as described above was dissolved in 20 ul of 5 x EcoRI methylase buffer, SAM was added to 80 uM, BSA was added to 0.4 mg/ml, water was added to bring the volume to 99 ul, and 1 ul of EcoRI methylase (20,000 units/ml, New England Biolabs) was added. The reaction was incubated at 37°C for 60 minutes. The reaction was then extracted 2 times with phenol and ethanol-precipitated. The methylated cDNA was collected by centrifugation and dried.
  • the cDNA was treated with DNA polymerase I (Klenow fragment) in the presence of deoxynucleoside triphosphates to make the ends of the cDNA blunt.
  • the cDNA was dissolved in 24 ul of IX DNA polymerase buffer containing 80 uM each dATP, dCTP, dGTP and dTTP. Two units of DNA polymerase (Klenow fragment) were added and the reaction mixture was incubated at 23°C for 10 minutes. EDTA was added to 20 mM and the cDNA was extracted two times with phenol, once with CHCl 3 , and ethanol-precipitated.
  • the cDNA which was EcoRI-methylated and blunt-ended, was collected by centrifugation, washed once with cold 70% ethanol, and dried. To prepare the linkers for addition to the cDNA, the linkers first had to be phosphorylated. 400 Picomoles of 8-base pair EcoRI linkers were phosphorylated in 1X polynucleotide kinase buffer with 20 uCi of [gamma- 32 P]-ATP and 5 units of polynucleotide kinase. The reaction was incubated at 37°C for 15 minutes. Unlabeled ATP was then added to 1 mM and the reaction was incubated at 37°C for 30 minutes.
  • the enzyme was inactivated by heating the reaction at 65°C for 10 minutes. 160 picomoles of the phosphorylated linkers were then ligated to the cDNA. The blunt-ended, methylated cDNA was dissolved in 10 ul of water, 160 picomoles of linkers were added, 10 x T4 ligase buffer was added to 1X, ATP was added to 1 mM, and 2 units of T4-DNA ligase (Boehringer-Mannheim) were added. The reaction mixture (a total of 20 ul) was incubated at 15°C for 16 hours. The ligase was inactivated by heating the reaction of 65°C for 10 minutes.
  • the ligation reaction was diluted with 5 ul of 10 x EcoRI buffer, 5 ul of 1 mg/ml BSA and 19 ul of water. Prior to addition of EcoRI, 1 ul of the mix was removed for analysis by gel electrophoresis. Ten units of EcoRI (New England Biolabs., 10 units/ul) were added and the reaction was incubated at 37°C for 1 hour. The reaction was extracted 1 time with phenol and run over a column of Sephadex G-100 equilibrated with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 0.1 M NaCl. The DNA in the excluded fractions was concentrated by use of a Centricon 30 microconcentration unit (Amicon) according to manufacturer's instructions.
  • the cDNA was loaded on 5-25% sucrose gradient in 50 mM Tris-HCl, pH 8.0, 1 mM EDTA and the gradients were centrifuged at 5°C at 38,000 r.p.m. for 17 hours in a Beckman SW41 rotor. Fractions were collected and were analysed by counting Cerenkov radiation. Parallel gradients were run with molecular weight markers. Fractions containing cDNA of approximately 1,000-base pairs and longer were pooled and the cDNA was concentrated with a Centricon 30 microconcentration unit. The cDNA was washed four times with 1 ml of H 2 O to remove the sucrose and was dried in vacuo.
  • Bacteriophage lambda gt10 DNA (Huynh, T.V. et al., Constructing and screening cDNA libraries in lambda gt10 and lambda gtll. In: D.M. Glover (ed.) DNA cloning. Vol. 1, IRL Press Oxford 1985, pp. 49-78) prepared by standard methods (Maniatis, et al., Molecular Cloning, Cold Spring Harbor, 1982) was linearized by digestion with EcoRI, phenol-extracted, and precipitated with ethanol.
  • the recombinant DNA was packaged into bacteriophage lambda heads for introduction into E. coli, by procedures described by Enquist and Sternberg, Methods Enzymol., 68:281-298 (1979).
  • Packaging extracts are available commercially (Promega Biotec, Madison, Wisconsin, and other sources) and were used according to the manufacturer's instructions.
  • the ligated DNA was mixed with the packaging extracts (50 ul), incubated at 23°C for 2 hours; the phages were diluted with 0.5 ml, 10 mM MgSO 4 , 10 mM Tris-HCl, pH 7.5, 0.01% gelatin, and a few drops of chloroform were added to the mixture.
  • the packaged phages were stored at 4°C.
  • E. coli strain BNN102 Huynh, T.V. et al., supra
  • E. coli strain BNN102 Huynh, T.V. et al., supra
  • the host strain was grown overnight at 37°C in LB-broth containing 0.2% maltose, to induce synthesis of the phage receptor in the host.
  • the cells were collected by centrifugation and resuspended in one-half volume of 10 mM MgSO 4 . Cells prepared in this manner were used for 1-2 days.
  • the phage were diluted serially in 10 mM MgSO 4 , 10 mM Tris-HCl, pH 7.5, and 0.01% gelatin. Fifty ul of diluted phage were added to 0.2 ml of E. coli cells, and the mixture was incubated at 37°C for 15 minutes to allow absorption of the phage. The infected cells were mixed with molten (47°C) LB broth containing 0.7% agar and poured on the LB-agar plate. After the top agar hardened, the plates were incubated at 37°C for 5-6 hours, at which time plaques could clearly be seen in the lawn of bacteria. A library of approximately 500,000 recombinant phages was obtained.
  • the lambda gt10 phage library was plated on twenty 15-cm petri dishes at a density of approximately 25,000 phage/plate. Duplicate nitrocellulose filter replicates were prepared for hybridization screening (Benton, W.D. and R.W. Davis, Science, 196:180 (1977)). Two 30-base synthetic oligonucleotides (GCG AAA CCA AGT TAC CCA CCG ACC TAC AAA and GCG AAA CCT TCT TAT CCG CCT ACC TAT AAG) were prepared with an Applied Biosystems DNA synthesizer.
  • sequences are two of the possible 98,304 coding sequences for the predominant decapeptide (ala-lys- pro-ser-tyr-pro-pro-thr-tyr-lys) of M. edulis bioadhesive precursor protein.
  • the oligonucleotides were radioactively labeled to a specific activity of approximately 10 8 cpm/ug with gamma-[ 32 P]-ATP (New
  • radioactive oligonucleotides (approximately 3.0 ug) were added to 250 ml hybridization solution containing 20% formamide, 6XSSC, 5X Denhardt's solution, 50 mM phosphate buffer (pH 6.8), 100 ug/ml sonicated denatured salmon sperm DNA and 10% dextran sulfate.
  • the filters were hybridized for 14 hours at 30°C, then washed five times briefly with 300 ml 6XSSC at 22°C, one time with 300 ml 1XSSC at 22°C and once at 42°C for 30 minutes with 500 ml 1XSSC.
  • the filters were air-dried and autoradiographed at -80°C with Kodak XAR X-ray film for 12 hours.
  • Plaques giving signals by autoradiography on the duplicate filters were purified by picking, diluting, plating and repeating the hybridization screen described above. Isolated individual plaques giving radioactive signals were picked and grown as plate lysates for DNA preparation as described (Maniatis, T. et al., "Molecular Cloning: A Laboratory Manual,” Cold Spring Harbor Laboratory, 1982, pp. 371-372).
  • EXAMPLE 5 DNA Sequence Analysis to Verify Clones DNA from lambda gt10 clone 14-1 and other clones with putative bioadhesive precursor protein cDNA inserts were digested with restriction endonuclease EcoRI. The EcoRI cDNA fragment was cloned into M13 mp11 (Norrander, J. et al., Gene, 26:101-106 (1983)). The bacteriophage M13 derivatives were constructed using methods described by Messing (Messing, J., Methods Bnzymol., 101:20-78 (1983)). Both orientations of the inserts were represented in independent clones. Some of the larger inserts were progressively shortened by the procedure of Dale et al.
  • Clones 14-1 and 52 share considerable homology in their 3'-ends. After a short untranslated trailer sequence in both clones, there is the polyadenylation signal AATAAA located just prior to a stretch of A residues. These features are expected at the authentic 3'-terminus of mRNA.
  • the partial bioadhesive precursor protein cDNAs shown in Figures 1-4 that were isolated and characterized as described in Examples 1-5 are used to isolate full-length bioadhesive precursor protein cDNA. This is accomplished through use of the initial clones as hybridization probes of more carefully prepared cDNA clone banks.
  • the mRNA used in Example 3 was prepared from mussels obtained in a grocery store that were not actively producing byssus threads and adhesive plaques. This may have resulted in low-level and poor quality adhesive protein mRNA.
  • fresh mussels were obtained directly by air freight delivery from the Blue Gold Sea Farms in Rhode Island.
  • the mussels had no treatment after harvesting other than tumbling to clean their outer shells.
  • the mussels were introduced into a 20-gallon aquarium tank placed in a 4°C room with 10 gallons of synthetic sea water (Instant Ocean, Aquarium Systems, Mentor, Ohio) heated to approximately 12-15°C. The tank water was mixed and the temperature regulated with a Precision H7B heater.
  • the mRNA is used to synthesize cDNA as described in Example 3. However, this time when the double-stranded cDNA is fractionated on a 5-25% sucrose gradient, a much more stringent size selection is used where only cDNA approximately 3,000 base pairs or larger is pooled for cloning.
  • the phage library and screening is carried out as described in Examples 3 and 4, except that the EcoRI insert fragment of clone 14-1 is isolated and made radioactive by nick translation (Rigby, P.W.J. et al., J. Molec. Biol. 113:237) with [alpha- 32 P]-dCTP label.
  • Bybridization is carried out at 42°C in 6XSSC, 50% formamide, with 5X Denhardt's solution and 100 ug/ml denatured salmon sperm DNA. The filters are washed at 50°C with 0.1 x SSC with 0.1% SDS. Hybridization-positive plaques identified in duplicate are purified and DNA is prepared as described in Example 4.
  • Clones with the largest insert size are selected for DNA sequence anlysis. Clones found with a characteristic 5'-terminal sequence and an open reading frame that codes for a protein of approximately 120,000 M.W. are full-length bioadhesive precursor protein cDNA clones.
  • Plasmid pGX2627 is derived from pGX1066 (on deposit at the American Type Culture Collection, Rockville, Maryland, and having accession number ATCC 39955). To derive pGX2627, a 514-base pair Rsal fragment from wild-type phage M13 containing the M13 origin of replication was inserted into the EcoRV site of pGX1066. The DNA sequence of pGX2627 is shown in Figure 7.) This plasmid contains a multi-restriction site sequence as shown in Figure 5(a).
  • Plasmid pGX2346 was constructed from pGX2287 by insertion of a synthetic oligonucleotide (Fig. 5b) between the Clal and SphI sites of pGX2287. Plasmid PGX2287 DNA was cut with Clal and ligated with synthetic DNA at high molar concentration. The ligated DNAs were then cut with SphI and ligated again at low concentration to form circles. Plasmid pGX2346 was identified by its decreased size and verified by DNA sequencing.
  • An in-frame gene fusion between the trpB portion of pGX2346, and the bioadhesive precursor protein cDNA of pGX2368 is constructed in the following manner: A Bcll endonuclease recognition site was first placed at the translation stop codon of pGX2368 by changing two bases as indicated in Figure 1 using oligonucleotidedirected mutagenesis (Zoller, M.J. and M. Smith, Methods Enzymol., 100:457-500, 1983) to create plasmid pGX2380. Both plasmids pGX2380 and pGX2346 are grown, for DNA preparation in an E.
  • coli host that contains the dam mutation (defective in DNA adenine methylase) so that they could be digested with Bcll.
  • the non-methylated pGX2346 DNA is cut with NotI and the pGX2380 DNA is cut with Xbal.
  • both DNAs are treated with E. coli DNA polymerase (Klenow fragment) to fill in the 5' single-stranded DNA overhangs.
  • the DNAs are then ligated at high DNA concentration (approximately 2 ug of each DNA in 20 ul) with T4 li gase.
  • the ligation product is cut with Bell then ligated again at low DNA concentration (approximately 1 ug total DNA in 150 ul volume) and used to transform E.
  • GX3015 A transformant with the desired construction (see Figure 6) is designated pGX2383.
  • GX3015 cells with plasmid pGX2383 produce a bioadhesive precursor protein of approximately 24,000 M.W. upon induction of the hybrid lambda promoter by a shift of growth temperature from 32 to 37°C.
  • Plasmid pGX2627 is derived from pGX1066 that has been deposited at the American Type Culture Collection (ATCC. 39955).
  • ATCC. 39955 American Type Culture Collection
  • a 514-base pair Rsal fragment from wild-type phage M13. containing the M13 origin of replication was inserted into the EcoRV site of pGX1066.
  • the DNA sequence of pGX2627 is shown in Figure 7.
  • Ten micrograms of plasmid pGX2627 DNA and twenty micrograms of lambda clone 52 DNA were cut with EcoRI.
  • the pGX2627 DNA was then treated with alkaline phosphatase. After phenol-chloroform extraction and ethanol precipitation using standard procedures in the art, one microgram of phosphatase-treated pGX2627 DNA and twelve micrograms of the EcoRI-cut lambda clone 52 DNA were ligated at 15°C in a twenty microliter volume with T4 polynucl ⁇ »otide ligase. After thirty minutes the ligation mixture was diluted to fifty microliters with ligation buffer and the reaction was continued for nine hours. The ligation mix was used to transform E.
  • a Bell endonuclease site was placed at the translation stop codon of the cDNA in pGX2377 by changing the two bases as indicated in Figure 2 using oligonucleotide-directed mutagenesis (J.M. Zoller and M. Smith, Methods Enzymol. 100:457-500, (1983)) to create pGX2381.
  • the mutagenic oligonucleotide. had the DNA sequence ACAGATATTGATCACAATATTA.
  • YpGX265GAL4 is on deposit at the American Type Culture Collection, Rockville, Maryland, having accession number ATCC 67233.
  • the YpGX265GAL4 vector contains the following functional units:
  • Terminator - derived from synthetic DNA-based on S. cerevisiae GAPDH transcription terminator.
  • 2-micron DNA - Derived from plasmid pJDB207 Provides plasmid replication origin for S. cerevisiae. E. coli replication origin - Derived from pJDB207.
  • YpGX265GAL4 is digested with restriction endonuclease Hindlll and the large and small DNA fragments are gel-purified. The small (3.65 Kb) fragment is saved for a later step.
  • Hindlll fragment is digested with restriction endonuclease Smal, generating two DNA fragments.
  • M13mp9 (commercially available) is digested with Smal and Hindlll and then treated with calf alkaline phosphatase.
  • the DNA molecules generated in steps 2 and 3 are ligated and used for transformation of E. coli.
  • the transformants containing phage double-stranded DNA with the yeast promoter-terminator cassette are identified.
  • the recombinant phage double-stranded DNA is digested with restriction endonucleases EcoRV and BamHI and the large fragment (approximately 8kb) is gel-purified.
  • Plasmid pGX2380 (prepared in accordance with Example 7 and containing bioadhesive precursor protein cDNA) is digested with restriction endonuclease Xbal, and the single-stranded overhang is filled with the Klenow fragment of DNA polymerase.
  • the DNA fragment generated in step 5 is digested with Bell.
  • the small DNA fragment (approximately 625bp) is gel-purified.
  • 5' ATCAAATCGATGGCGGCC and 5' GGCCGCCATCGATTTGAT are annealed and used in a three-way ligation with the DNA fragments generated in steps 5 and 7.
  • E. coli transformants containing the desired phage DNA molecules are identified by restriction endonuclease digestions .
  • the phage DNA generated in step 9 is digested with restriction endonucleases Smal and Hindlll and the small fragment (approximately 1300bp) is gel-purified.
  • YpGX265GAL4 is digested with Smal and Hindlll and the large fragment is gel-purified.
  • YpGX285 The DNA molecules generated in steps 10 and 11 are ligated and E. coli is transformed.
  • YpGX285 is linearized with restriction endonuclease Hindlll and treated with calf alkaline phosphatase.
  • step 14 The 3.65 kb GAL4-containing fragment from step 1 is ligated with the linearized YpGX285 generated in step 13.
  • E. coli is transformed and the desired plasmid, YpGX285GAL4, is identified by restriction endonuclease analysis.
  • Saccharomyces strains carrying mutations in the LEU2 structural gene are transformed with YpGX285GAL4 by standard methods.
  • a suitable strain is AH22 (ATCC #38626).
  • the yeast strain is grown in YNBD medium to maintain the plasmid.
  • the YNBD medium contains 0.7% yeast nitrogen base, 2% glucose, and 20 mg/liter L-histidine.
  • the strain is grown in medium containing 1% yeast extract, 2% peptone, 1% glucose, and 1% galactose at 30°C with shaking.
  • bioadhesive precursor protein is analyzed by Western Blot and SDS-polyacrylamide gel electrophoresis of the yeast proteins following procedures known in the art.
  • Plasmid pGX2383 contains the bla, gene which encodes beta-lactamase providing ampicillin resistance, as well as the trpED that in tryptophan-deficient medium complements the trpED102 deletion in the GX3015 chromosome.
  • GX3015 A single colony of GX3015 (pGX2383) is picked after growth on minimal salts medium (Miller, J.B., "Experiments in Molecular Genetics,” Cold Spring Barbor Laboratory, 1972, p. 432) supplemented with 0.4% casamino acids and 0.4% glucose and inoculated into 5 ml of LB medium supplemented with 100 ug/ml ampicillin. After reaching an optical density (A 600 ) of greater than 1.0, 0.4 ml of the culture is inoculated into each of two 250-ml baffled flasks containing 50 ml of LB broth supplemented with 100 ug/ml ampicillin. The two flasks are incubated at 30oC and shaken at 250 r.p.m. for 6.5 to 9 hours.
  • Fermentation is carried out using 8 liters of the following initial medium:
  • Biotin (0.5 mg/ml in 95% ethanol) - 12 ml tap water to 8 liters, autoclave
  • the feed solution is prepared as follows:
  • the feed solution is initially added to the broth in a volume of 180 ml and thereafter as needed to maintain the glucose level at 10 g/liter. Feed supplementation is continued until the A 600 reaches 20, at which time the cells are induced to express bioadhesive precursor protein from the hybrid lambda promoter. Induction is effected by raising the temperature to 37°c to deactivate the temperature-sensitive lambda cI857 represser protein produced by the defective lysogen in the GX3015 chromosome. The fermentation is maintained at 37°C for another 6-8 hours.
  • EXAMPLE 11 Purification of Bioadhesive Precursor Protein
  • E. coli GX3015 (pGX2383) cells (32 g wet weight) are suspended in 20 ml 20 mM Tris-HCl, 2mM EDTA (pH 7.5), 1 mM phenylmethylsufonyl fluoride, 25 mM iodoacetic acid, and thoroughly disrupted by passage through a French press followed by sonication.
  • the cell debris and protein-containing inclusion bodies containing bioadhesive precursor protein are pelleted by centrifugation at 27,500 g for 30 minutes at 4°C.
  • the pellet is extensively washed by suspension in 10 mM Tris-HCl, 1 mM EDTA (pH 7.5) and centrifugation. Washing is continued until the supernatant is clear.
  • the pellet is then dissolved in 15 ml of 6 M guanidine hydrochloride, 5% beta-mercaptoethanol, 25 mM iodoacetic acid, and centrifuged at 30,000 xg for 30 minutes at 4°C.
  • the supernatant is dialyzed against 4 liters of 0.2 mM EDTA, 10 mM iodoacetic acid, with 3 changes which results in protein precipitation.
  • the precipitate containing about 0.5 g of protein is dissolved in 40 ml of 70% formic acid.
  • Cyanogen bromide (1.3 g). is added and the solution is allowed to react overnight at room temperature. After rotary evaporation, the residue is extracted with 20 ml water (pH 4.0 from residual formic acid). The pH of the water-soluble fraction is adjusted to pH 7.0 with 5N KOH resulting in some precipitate formation. The supernatant is then applied to a CM cellulose or S-Sepharose column (1.5 x 26 cm) equilibrated with 50 mM potassium phosphate (pH 7.0).
  • the bioadhesive precursor protein is eluted with either a salt gradient (0 to 0.5 M KCl) or a pH change (pH 8 to pH 10) in the buffer.
  • the fractions are assayed by measurement of absorbance at 280 nm and by SDS polyacrylamide gel electrophoresis using both coomassie blue protein stain and the Western blot assay with specific antibodies (Example l).
  • the fractions containing the bioadhesive precursor protein are pooled and dialyzed overnight twice against 2 liters of deionized water. The resultant suspension is lyophilized and 1 mg of purified material is obtained.
  • Material could be further purified, if necessary, using Sephadex G-75 column chromatography with Q3M ammonium acetate pH 4.0. Folyphenolic protein eluting in the first protein peak is dialyzed against water and lyophilized for recovering as a salt-free powder.
  • the purified protein is hydrolyzed in 6 M constant boiling BCl with phenol crystal i n vacuo at 105°C for 24 hours.
  • the amino acids in the acid hydrolysate are identified as O-phthaldehyde (OPA) derivatives which are separated on C 18 reverse-phase BPLC column (Fleury, M.O. and D.V. Ashley, Anal. Biochem., 133:330-335 (1983)).
  • OPA O-phthaldehyde
  • the amino acid composition is used to verify purity since only a subset of amino acids is present in bioadhesive precursor protein.
  • E. coli cells [GX3015 (pGX2383)] or yeast cells [AH22(YpGX285GAL4)] from a 180 1 fermentation are centrifuged in a Westphalia centrifuge, washed with saline and resuspended as a 30% solids suspension in 10 mM EDTA, 1.0 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM iodoacetic acid (IAA) at pH 8.0 before breaking by a Manton-Gaulin homogenizer.
  • Bioadhesive precursor protein present in an insoluble fraction is collected with the cell debris upon Westphalia centrifugation.
  • the centrifugation pellet is made a 20% solids suspension in acetic or formic acid at pH 2.2 to 2.5 and mixed for several hours to solubilize bioadhesive precursor protein.
  • the extract is centrifuged or filtered to remove solids and the clear filtrate solution is then adjusted to pH 4 with 5 N KOH in the presence of 10 mM EDTA, 10 mM IAA and 1.0 mM PMSF. Impurities are removed as a precipitate by filtration or centrifugation.
  • the polyphenolic protein in the clear supernatant is then concentrated by ultrafiltration (10,000 M.W. cutoff membrane) and subsequently lyophilized.
  • the pH of the solution is adjusted to 4 with acetic acid and the solution is dialyzed against 100 volumes of 5% acetic acid.
  • the samples are rotatory-evaporated to reduce the volume.
  • the tyrosinase is removed either by using a LH-Sephadex 60 column, which is eluted with 0.2 M acetic acid, or using a membrane filtration method (Amicon PM30, cut off of 30,000 M.W.).
  • Microbially produced and hydroxylated mussel bioadhesive protein coated onto a surface can be used as a pretreatment or priming substance for conventional adhesives.
  • An example of the use of mussel bioadhesive protein as a primer treatment for bonding two pieces of aluminum is given below.
  • Hydroxylated bioadhesive protein prepared as in Example 13 is dissolved in degassed water (optimally at pH 7.0 to 8.0) at a concentration of 10-400 mg/ml (10-40% w/v). The solution is maintained under nitrogen to prevent premature oxidation of DOPA residues to quinones and curing of the adhesive primer.
  • the bioadhesive protein solution is sprayed or painted to uniformly moisten an oil-free aluminum surface in a normal air environment.
  • the surface is then dried in a low-humidity environment.
  • a brown or tan color may develop indicating quinone oxidation and chemical cross-linking.
  • the primed surfaces to be bonded are then joined using standard materials such as epoxy glue.
  • an enzyme such as mushroom tyrosinase (Ito et al., Biochemistry, 222:407-411 (1984)) or Streptomvces tyrosinase (Lerch and Ettlinger, Eur. J. Biochem., 31:427-437 (1972)) is mixed with the non-hydroxylated protein (Example 11) immediately prior to application (for example, in the nozzle of a spray applicator) at a concentration of 0.01 to 1.0 mg/ml solution.
  • the enzyme under these conditions effects oxidation all the way from tyrosine to the reactive quinone species.
  • Blends of bioadhesive protein with other polymers are also used as primers for other adhesives.
  • the hydroxylated bioadhesive protein prepared as in Example 13 is dissolved at a concentration of 1- 700 mg/ml (0.1-70% solids) in water (or a physiological salt solution for medical applications) adjusted to pH 6.0 with dilute acids.
  • a basic solution (approximately 1/50 volume) is added to increase the pH to 8.0.
  • An enzyme such as mussel catechol oxidase (Waite, J.H., J. Mar. Biol. Assoc., 65:359-371 (1985)) can also be added (final concentration 0.01-1 mg/ml) in place of or in addition to base solution immediately prior to application to accelerate the oxidation of DOPA residues to quinones to yield more rapid curing.
  • Mixing of components immediately prior to application can occur, for example, in a spray head of a Duploject syringe as has been described for fibrin sealant (Redl, H. and G.
  • bioadhesive protein is naturally associated with collagen in the byssal threads of the mussels.
  • Collagen is one natural polymer that can be used to increase the cohesive strength of phenolic protein composites.
  • Acid-soluble collagen (Gallop, P.M. and S. Seifter, Methods
  • Enzymol., VI:635-641 (1963)) is dissolved in dilute acid solution at 10-70% (w/v).
  • the collagen is mixed with the bioadhesive protein mixtures as described in
  • Example 15 in ratios having from 1% to 50% of the solids comprising bioadhesive protein with total solids ranging from 10 to 70%. Higher percentages of bioadhesive protein yield more highly cross-linked rigid composites than those with lower percentages of bioadhesive protein.
  • Alkaline solution may be used to neutralize the mixture immediately prior to application. This allows more rapid oxidation and cross-linking (curing) of the mixture. Also, at neutral pH, the collagen will crystallize providing added cohesive strength.
  • bioadhesive protein is used in combination with preformed sheets of collagen.
  • This method is analogous to the use of reinforcing steel in cement or graphite fiber in epoxy composites.
  • Collagen sheets such as the commercially available collastat (a Helitrex product distributed by American Home Products Corporation) or other similar products are sprayed or soaked in bioadhesive protein activated as described above in Example 13, then applied to the surface to be bonded.
  • insoluble or crystalline protein sheets can be used as reinforcement for adhesive protein.
  • silk cloth, or sheets formed from solubilized and reprecipitated alpha-keratose from wool keratin fibers J. De Bersagbes, Curr. Probl. Dermatol., 6:34-86 (1976)
  • polymerized fibrin clot formed from purified fibrinogen, thrombin and Factor VIII Redl, H. and G. Schlag, Facial Plastic Surgery, 2:315-321 (1985)
  • the use of sheets of fibrin may have the additional benefit of helping to promote wound healing (Redl and Schlag, supra).
  • Chitosan is dissolved in 1% acetic acid to a concentration of 30-150 mg/ml (3-15% w/v).
  • the chitosan solution with a final pH of approximately 6.0 is blended with the bioadhesive protein solution described in Example 15. Blends typically have bioadhesive protein concentrations between 2 and 30% and chitosan concentrations between 1 and 7%.
  • pH 6.0 where the chitosan is still soluble catechol oxidase and tyrosinase addition catalyzes the formation of reactive DOPA-derived quinones and cross-linking.
  • Increasing the pH to 8.0 as in Example 15 prior to application results in the immediate precipitation of chitosan out of solution which in some cases may not be desirable.
  • RNA was isolated from fresh M. edulis as described in Example 6. Two 18-base probes were synthesized based on the DNA sequence in clone 14. The first synthetic probe (#2214 - GTTTGTTGGTTTATATGC) was complementary to a conserved sequence close to the 3'-end of the coding sequence. This oligonucleotide was also used to prime cDNA synthesis. The second probe (#2213-TTTATAAGTTGGCTTTGC) was the complement of the sequence that codes for the hexapeptide found in several locations in the cDNA clones. Probes 2213 and 2214 were used together since they have the same GC/AT ratio and thus approximately the same melting temperature.
  • the use of both probes provided multiple hybridization points and a strong signal during clone bank screening.
  • the clone bank prepared as in Example 6 was screened with the 18-base oligonucleotides. Thirty hybridization-positive clones were initially identified in duplicate. Twenty-eight of those were plaque purified with two rounds of plating and screening, and their DNA was analyzed.
  • a third synthetic 18-base probe (#2231-GGGATATATTGACTTGGA), which encodes a portion of an uncommon, variant decapeptide, was included in this hybridization analysis.
  • this clone appears to encode a very large middle portion of the mussel adhesive protein and contains 76 continuous tandem repeats of decapeptides and hexapeptides throughout the 2.1 kb length of the clone (Figure 9). Gaps in the sequence shown in Figure 9 allow optimal alignment of the hexapeptides with the decapeptides. Of the 63 decapeptides in the N1 protein, 31 are identical to the decapeptide described in U.S. Patent 4,585,585. The variations in each position are shown in Figure 10. Of the 13 hexapeptides, 10 are Ala-Lys-Pro-Thr-Tyr-Lys, two have Ser instead of Ala, and one has Val instead of Ala.
  • Clone N1 does not have a perfect overlap with any of the other cDNA clones sequenced to date. While it is possible that N1 lies just upstream of carboxy-terminal clones 52 or 14, it is also possible that the lack of perfect overlap in any of these clones is the result of multiple polyphenolic protein genes or alternate splicing patterns, as found in the studies of other structural proteins. Clone N1 also does not have a characteristic 5'-end sequence and therefore probably does not encode the N-terminus. However, it encodes a polyphenolic protein of nearly 80,000 molecular weight and therefore constitutes the majority of the 110,000-130,000 intact mussel protein.
  • tandem deca- and hexapeptide repeats may constitute the complete functional part of this protein with respect to adhesive properties.
  • EXAMPLE 19 Expression of Nl cDNA in Yeast
  • vector M13mpl8 was first mutagenized by oligonucleotide directed mutagenesis to insert a NotI site adjacent to the unique EcoRI site. An oligonucleotide of sequence.
  • the new M13 vector was called MGX463 and has unique NotI and BAMHI restriction sites bordering the EcoRI site.
  • MGX463 double-stranded DNA was digested with EcoRI and treated with calf-alkaline phosphatase and the linear DNA was purified on a 0.8% agarose gel.
  • the Nl cDNA coding sequence was removed from an Ml3mpl0 vector by digesting double-stranded DNA with EcoRI. The approximately 2200 base pair EcoRI fragment was gel purified. This fragment was ligated with the MGX463 double-stranded DNA which was linearized with EcoRI and treated with calf alkaline phosphatase. E. coli strain GX1210 was transformed with the ligation mix. This resulted in vector MGX464 which carries the Nl cDNA sequence bordered by NotI and BamHI restriction sites. MGX464 was digested with NotI and BamHI and the Nl cDNA fragment was gel purified. YpGX283 (fully described in commonly assigned co-pending U.S.
  • Patent Application Serial No. 025,243, filed March 12, 1987, and shown in Figure 11 was digested with NotI and BamHI and the large vector fragment was gel purified. This fragment was ligated with the Notl/BamHI N1 cDNA fragment and E. coli strain GX1210 was transformed, resulting in plasmid YpGX405.
  • Plasmid YpGX405 ( Figure 12) is a yeast E. coli shuttle vector which contains the N1 cDNA sequence positioned between the PH05 signal coding sequence and the GAPDH transcription terminator. Expression is directed by a hybrid promoter composed of elements of the yeast GAL1 and MF-alpha 1 promoters.
  • Vector YpGX283GAL4 (fully described in co-pending commonly assigned U.S. Patent Application Serial No. 025,243, filed March 12, 1987), was digested with Hindlll and the GAL4 gene was gel purified. These two fragments were ligated and E. coli strain GX1210 was transformed, resulting in YpGX405GAL4.
  • yeast strain D8 transformed with expression vector YpGX405GAL4 first grown on YNBD solid medium (0.7% yeast nitrogen base, 10% glucose, 2% agar) and then inoculated into 10 ml YPD (1% yeast extract, 2% peptone, 2% glucose) so that the initial A 600 reading was 0.1 and was then grown at 28°C with shaking for 17-24 hours.
  • the cells were harvested and washed with 10 ml YPGal (1% yeast extract, 2% peptone, 2% galac tose) and resuspended in an equal volume of YPGal and induced for 6-28 hours.
  • T 25 E 125 pH 8.4 buffer 25 mM Tris-HCl, 125 mM EDTA, pH 8.4
  • the cells were then resuspended in 100 ul T 25 E 125 buffer, and broken by vortexing in the presence of glass beads.
  • 200 ul T 25 E 125 the cell lysate was removed from the glass beads and cell debris was pelleted in a microfuge for five minutes.
  • the insoluble pellet was resuspended in 200 ul sample buffer (Laemmli, U.K. 1970, Nature 227:680-685) and boiled for five minutes.
  • EXAMPLE 20 Purification of Bioadhesive Precursor Protein Yeast cells as a 30% suspension in 20 mM Tris pH 7.5, 2 mM EDTA, 0.1 mM PMSF, 10 mM iodoacetic acid were thoroughly disrupted mechanically by a French Press, sonicator or a Manton Gaulin homogenizer. The adhesive precursor protein present in the insoluble fraction was collected with cell debris by centrifugation at 25,000 g for 30' at 4°C. The pellet was extensively washed with 10 mM Tris, 1 mM EDTA (pH 7.8) and centrifuged as before.
  • the pellet was resuspended as a 30% suspension in formic acid (final concentration of 70%) and mixed for several hours. Cyanogen bromide (50 gm/l) was added and the suspension was stirred for 24 hours at room temperature. The reaction mixture was then rotary evaporated to dryness, and the residue was resuspended to the original lysis volume with water (pH 3.0) and stirred for several hours to extract the adhesive protein.
  • the adhesive precursor protein was precipitated from the supernatant with 10% NaCl.
  • the precipitate was then dissolved in guanidinium chloride (final concentration 6 M, pH 8.0) with 5% 2-mercaptoethanol and chromatographed on a Sephacryl S-300 or S-400 column, depending on the size of the adhesive precursor protein.
  • the fractions containing the adhesive precursor protein were pooled, adjusted to pH 4.0 with glacial acetic acid, dialyzed against 5% acetic acid, then 0.1% acetic acid, with several changes of the dialysis solution, and lyophilized.
  • the purified protein was characterized by its mobility on SDS-polyacrylamide gel electrophoresis using both Coumassie blue stain and Western blot analysis, its UV absorption spectrum, protein quantitation and amino acid composition analysis.
  • EXAMPLE 21 The yeast cells were processed as in Example 20 up to the 10% NaCl precipitation step. Instead of treating with NaCl, the supernatant was adjusted to pH 5.2 and centrifuged. The clear supernatant was dialyzed against 10% formic acid and slowly to water and then to 30 mM phosphate buffer (pH 7.3). After centrifugation, the supernatant was chromatographed on a weak cation exchanger. The column was eluted first with a 0.2-1 M salt gradient at pH 7.3, followed by 1M NaCl in 5% acetic acid. The fractions containing the adhesive precursor protein were pooled, dialyzed and lyophilized as in Example 20, and the identity and purity of the adhesive precursor protein were determined as describee in Example 20.
  • EXAMPLE 22 After the yeast cells were broken and centrifuged as in Example 20, the pellet was solubilized in either 6 M guanidinium chloride or 8 M urea with 5% 2-mercaptoethenol. The insoluble cellular components were removed by centrifuging at 25,000 g for 30' at 4°C. The protein in the supernatant was precipitated by dialysis against water, and the adhesive precursor protein was extracted by a dilute formic acid or acetic acid solution (pH 2.0) for several hours. The adhesive precursor protein was precipitated by either adjusting the pH to neutral, or making the solution 10% NaCl.
  • the adhesive precursor protein pellet was dissolved in 6M guanidinium chloride and chromatographed on an S-300 or S-400 column depending on the size of the protein.
  • the adhesive precursor protein, with the correct size, was pooled, adjusted to pH 4.0 with acetic acid, dialyzed against 5% acetic acid then 0.1% acetic acid and lyophilized.
  • Example 20 The yeast cells were broken and thoroughly washed as in Example 20. The pellet was extracted for several hours with dilute formic or acetic acid (pH
  • the solution was then adjusted to pH 3.0 and centrifuged.
  • the adhesive precursor protein present in the supernatant was precipitated when the pH was adjusted to between 5.0 and 5.5.
  • the adhesive precursor protein was collected by centrifugation, and, if necessary, further purified by either a weak cation exchange, or a gel filtration column as described in Examples 20 and 21.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Vecteurs capables d'exprimer, dans des transformants microbiens, une protéine ayant la séquence native d'acides aminés d'une protéine précurseur bioadhésive d'un animal marin sélectionné parmi un groupe comprenant les moules, les bernacles et les huîtres. La protéine precurseur bioadhésive peut être exprimée dans des transformants, elle peut être récupérée et convertie en une protéine bioadhésive par hydroxylation.
PCT/US1987/003048 1986-11-24 1987-11-24 Bioadhesifs WO1988003953A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP88501325A JPH02501706A (ja) 1986-11-24 1987-11-24 生物学的接着物質
DK414688A DK414688D0 (da) 1986-11-24 1988-07-22 Bioklaebemidler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93394586A 1986-11-24 1986-11-24
US933,945 1986-11-24
US8245687A 1987-08-07 1987-08-07
US082,456 1987-08-07

Publications (1)

Publication Number Publication Date
WO1988003953A1 true WO1988003953A1 (fr) 1988-06-02

Family

ID=26767474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/003048 WO1988003953A1 (fr) 1986-11-24 1987-11-24 Bioadhesifs

Country Status (5)

Country Link
EP (1) EP0332660A4 (fr)
JP (1) JPH02501706A (fr)
AU (1) AU1180488A (fr)
DK (1) DK414688D0 (fr)
WO (1) WO1988003953A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242656A2 (fr) * 1986-04-25 1987-10-28 Bio-Polymers, Inc. Méthode de production de protéines bioadhésives, contenant de la dopa, à partir de protéines contenant de la tyrosine
EP0304486A1 (fr) * 1987-03-12 1989-03-01 Enzon Labs Inc. Production d'analogues de proteines precurseur bioadhesifs par des organismes mis au point genetiquement
US5197973A (en) * 1990-12-14 1993-03-30 Creative Biomolecules, Inc. Synthetic bioadhesive
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
EP0829537A1 (fr) * 1995-05-09 1998-03-18 Fujikawa, Yoshio Proteine de perle (nacreine) et son procede de production
WO2000015789A1 (fr) * 1998-09-09 2000-03-23 United States Surgical Corporation Analogues recombinants de proteines bioadhesives contenant de l'hydroxyproline
WO2001044401A1 (fr) * 1999-12-17 2001-06-21 Magnus Qvist Nouvelle utilisation d'une composition bioadhesive contenant une proteine polyphenolique
EP1589088A1 (fr) * 1999-12-17 2005-10-26 BioPolymer Products of Sweden AB Nouvelle composition bioadhésive comprenant une protéine polyphénolique bioadhésive, un polymère avec des groupes carbohydrates, des filaments minces pharmaceutiquement acceptables et sa utilisation
WO2006000209A1 (fr) * 2004-06-29 2006-01-05 Jennissen Herbert P Polypeptide lie a un groupe organique
US7618937B2 (en) 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US7622533B2 (en) 2006-08-04 2009-11-24 Nerites Corporation Biomimetic compounds and synthetic methods therefor
EP2407542A1 (fr) * 2004-07-28 2012-01-18 National Research Council Of Canada Vaccins recombinants contre les copépodes caligides (poux du poisson) et séquences d'antigène associées
US8911831B2 (en) 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
US9320826B2 (en) 2010-11-09 2016-04-26 Kensey Nash Corporation Adhesive compounds and methods use for hernia repair

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496397A (en) * 1984-03-07 1985-01-29 University Of Connecticut Process for purifying and stabilizing catechol-containing proteins and materials obtained thereby
US4585585A (en) * 1984-03-07 1986-04-29 University Of Connecticut Research & Development Corporation Decapeptides produced from bioadhesive polyphenolic proteins
US4687740A (en) * 1984-03-07 1987-08-18 University Of Connecticut Research & Development Corp. Decapeptides produced from bioadhesive polyphenolic proteins
JPS6485400A (en) * 1987-07-16 1989-03-30 Montefibre Spa Felt and nonwoven fabric based on polyester fiber and glass fiber and its production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68813T1 (de) * 1986-04-25 1991-11-15 Bio Polymers Inc Klebstoffderivate von bioadhaesiven polyphenolproteinen.
DK163987A (da) * 1986-04-25 1987-10-26 Bio Polymers Inc Fremgangsmaade til fremstilling af dopa-holdige bioklaebende proteiner ud fra tyrosin-holdige proteiner

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496397A (en) * 1984-03-07 1985-01-29 University Of Connecticut Process for purifying and stabilizing catechol-containing proteins and materials obtained thereby
US4585585A (en) * 1984-03-07 1986-04-29 University Of Connecticut Research & Development Corporation Decapeptides produced from bioadhesive polyphenolic proteins
US4687740A (en) * 1984-03-07 1987-08-18 University Of Connecticut Research & Development Corp. Decapeptides produced from bioadhesive polyphenolic proteins
JPS6485400A (en) * 1987-07-16 1989-03-30 Montefibre Spa Felt and nonwoven fabric based on polyester fiber and glass fiber and its production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Abstracts of the Annual Meetings of the American Society for Microbiology, Volume 83, issued 1983, G.M. THORNE et al, "Cloning of Adhesive Antigen Serotype 3 from Enterotoxigenic E. Coli Strain D542," see page 60. *
Genetic Engineering News, issued April 1985, R. JOHNSON, "Genex Seeks to Clone Mussel Glue Protein", see pages 14 and 18. *
See also references of EP0332660A4 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242656A2 (fr) * 1986-04-25 1987-10-28 Bio-Polymers, Inc. Méthode de production de protéines bioadhésives, contenant de la dopa, à partir de protéines contenant de la tyrosine
EP0242656A3 (en) * 1986-04-25 1989-04-19 Bio-Polymers, Inc. Method for making dopa-containing bioadhesive proteins from tyroshine-containing proteins
EP0304486A1 (fr) * 1987-03-12 1989-03-01 Enzon Labs Inc. Production d'analogues de proteines precurseur bioadhesifs par des organismes mis au point genetiquement
EP0304486A4 (en) * 1987-03-12 1990-12-05 Genex Corporation Production of bioadhesive precursor protein analogs by genetically-engineered organisms
US5197973A (en) * 1990-12-14 1993-03-30 Creative Biomolecules, Inc. Synthetic bioadhesive
US5374431A (en) * 1990-12-14 1994-12-20 Creative Biomolecules, Inc. Synthetic bioadhesive
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US6127348A (en) * 1991-05-31 2000-10-03 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
EP0829537A4 (fr) * 1995-05-09 2000-05-03 Fujikawa Yoshio Proteine de perle (nacreine) et son procede de production
EP0829537A1 (fr) * 1995-05-09 1998-03-18 Fujikawa, Yoshio Proteine de perle (nacreine) et son procede de production
WO2000015789A1 (fr) * 1998-09-09 2000-03-23 United States Surgical Corporation Analogues recombinants de proteines bioadhesives contenant de l'hydroxyproline
WO2001044401A1 (fr) * 1999-12-17 2001-06-21 Magnus Qvist Nouvelle utilisation d'une composition bioadhesive contenant une proteine polyphenolique
US6867188B2 (en) 1999-12-17 2005-03-15 Biopolymer Products Of Sweden Ab Use of a bioadhesive composition comprising a polyphenolic protein
EP1589088A1 (fr) * 1999-12-17 2005-10-26 BioPolymer Products of Sweden AB Nouvelle composition bioadhésive comprenant une protéine polyphénolique bioadhésive, un polymère avec des groupes carbohydrates, des filaments minces pharmaceutiquement acceptables et sa utilisation
US7618937B2 (en) 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US8911831B2 (en) 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
EP1939211A1 (fr) * 2004-06-29 2008-07-02 Morphoplant GmbH Polypeptide lié à un groupe organique
WO2006000209A1 (fr) * 2004-06-29 2006-01-05 Jennissen Herbert P Polypeptide lie a un groupe organique
EP2407542A1 (fr) * 2004-07-28 2012-01-18 National Research Council Of Canada Vaccins recombinants contre les copépodes caligides (poux du poisson) et séquences d'antigène associées
US8207132B2 (en) 2004-07-28 2012-06-26 National Research Council Of Canada Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof
US7622533B2 (en) 2006-08-04 2009-11-24 Nerites Corporation Biomimetic compounds and synthetic methods therefor
US9320826B2 (en) 2010-11-09 2016-04-26 Kensey Nash Corporation Adhesive compounds and methods use for hernia repair

Also Published As

Publication number Publication date
EP0332660A4 (en) 1990-12-05
JPH02501706A (ja) 1990-06-14
EP0332660A1 (fr) 1989-09-20
DK414688A (da) 1988-07-22
DK414688D0 (da) 1988-07-22
AU1180488A (en) 1988-06-16

Similar Documents

Publication Publication Date Title
US5049504A (en) Bioadhesive coding sequences
US5202236A (en) Method of producing bioadhesive protein
US5202256A (en) Bioadhesive precursor protein expression vectors
US5242808A (en) Production of bioadhesive precursor protein analogs by genetically engineered organisms
Ichinose et al. Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase
WO1988003953A1 (fr) Bioadhesifs
NZ211666A (en) Pharmaceutical compositions comprising tumour necrosis factor and its production via recombinant techniques
JPH053790A (ja) デヒドロペプチダーゼ−ｉ
JPH0650990B2 (ja) トロンビン阻害剤の製造方法
EP0338634B1 (fr) Polypeptides d'après le venin de vipère et leur expression génétique
JPH01501840A (ja) 繊維芽細胞成長因子の産生
CA1341101C (fr) Enzyme .alpha.-amidante c-terminal recombinante
JPH05247090A (ja) 抗トロンビンポリペプチド
WO1988007076A1 (fr) Production d'analogues de proteines precurseur bioadhesifs par des organismes mis au point genetiquement
US5049658A (en) Polypeptide with cell-spreading activity
JPH05199882A (ja) ビリルビンオキシダーゼの製造法
JP2686025B2 (ja) ブラストサイジンｓデアミナーゼ遺伝子
SU1614765A3 (ru) Способ получени рекомбинантной плазмидной ДНК pHTN 713, кодирующей фактор некроза опухоли человека
IE890559L (en) A hirudin derivative
JPS6371179A (ja) Ｌ―フェニルアラニン―アンモニアリ・アーゼ構造遺伝子
AU703180B2 (en) Recombinant alpha-galactosidase enzyme and cDNA encoding said enzyme
JPH01501037A (ja) 有機化合物の又はそれに関連する改良
HU214698B (hu) Eljárás rekombináns deszulfátó-hirudin HV-1 peptidek előállítására
US5187078A (en) Plasma-type glutathione peroxidase gene and application of the same
CA2089752A1 (fr) Production de lysozyme humain dans des cellules de levure methylotrophes et sa secretion dans le milieu de culture

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988900964

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988900964

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988900964

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载